The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial
Open accessAbstract
OBJECTIVE: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer's disease. DESIGN: A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran. METHODS: Patients with mild to moderate Alzheimer's disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of >or= 12 on the cognitive subscale of Alzheimer's disease assessment scale (ADAS-cog) and <or= 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded. RESULTS: At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p < 0.0001). There were no significant differences in the two groups in terms of observed side effects except agitation, which was more common in the placebo group (p = 0.03). CONCLUSIONS: Melissa officinalis extract is of value in the management of mild to moderate Alzheimer's disease and has a positive effect on agitation in such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.262.18.2551 · Cited by 1,626
The Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Evans, D. A., Funkenstein, H. H., Albert, M., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989) · PubMed · Cited by 599
Prevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Ballard, C. G., O'Brien, J. T., Reichelt, K., & Perry, E. K. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0703 · Cited by 396
Medicinal plants and Alzheimer’s disease: From ethnobotany to phytotherapy
Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. L. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772808 · Cited by 285
The cholinergic hypothesis of Alzheimer's disease: a review of progress
BABIC;, T., FRANCIS, P. T., PALMER, A. M., SNAPE, M., & WILCOCK, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.4.558 · Cited by 255
Kennedy, D. O., Scholey, A. B., Tildesley, N. T. J., Perry, E. K., & Wesnes, K. A. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00777-3 · Cited by 249
Cited by
Kennedy, D. O., & Wightman, E. L. (2011) · Advances in Nutrition · doi:10.3945/an.110.000117 · Cited by 684
Abraha, I., Rimland, J. M., Trotta, F. M., Dell'Aquila, G., Cruz-Jentoft, A., Petrovic, M., Gudmundsson, A., Soiza, R., O'Mahony, D., Guaita, A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012759 · Cited by 557
Management of agitation and aggression associated with Alzheimer disease
Ballard, C. G., Gauthier, S., Cummings, J. L., Brodaty, H., Grossberg, G. T., Robert, P., & Lyketsos, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.39 · Cited by 404
Melissa officinalis L. – A review of its traditional uses, phytochemistry and pharmacology
Shakeri, A., Sahebkar, A., & Javadi, B. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.05.010 · Cited by 386
Reddy, P. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03530.x · Cited by 358
Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders
Zhang, Z.-J. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.014 · Cited by 344
Akhondzadeh, S., Noroozian, M., Mohammadi, M., Ohadinia, S., Jamshidi, A. H., & Khani, M. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00463.x · Cited by 344
Self-citationManagement of oxidative stress and other pathologies in Alzheimer’s disease
Simunkova, M., Alwasel, S. H., Alhazza, I. M., Jomova, K., Kollar, V., Rusko, M., & Valko, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02538-y · Cited by 303
Akhondzadeh, S., Shafiee Sabet, M., Harirchian, M. H., Togha, M., Cheraghmakani, H., Razeghi, S., Hejazi, S. S., Yousefi, M. H., Alimardani, R., Jamshidi, A., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1706-1 · Cited by 268
Self-citationAkhondzadeh, S., Sabet, M. S., Harirchian, M. H., Togha, M., Cheraghmakani, H., Razeghi, S., Hejazi, S. S., Yousefi, M. H., Alimardani, R., Jamshidi, A., et al. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01133.x · Cited by 249
“It has been reported that Melissa officinalis (lemon balm) and Salvia officinalis (sage) improve cognitive function and reduces agitation in patients with mild to moderate AD (11, 12).”
Self-citationAndrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092313 · Cited by 240
Can herbs provide a new generation of drugs for treating Alzheimer’s disease?
Anekonda, T. S., & Reddy, P. H. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.09.001 · Cited by 140
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
“of lemon balm had a good effect on cognitive performance in healthy participants and patients with AD, with no side effects (Akhondzadeh et al., 2003; Kennedy et al., 2002, 2003).”
BackgroundTraditional used Plants against Cognitive Decline and Alzheimer Disease
Eckert, G. P. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00138 · Cited by 47
Metadata
- Authors
- Akhondzadeh, S.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2003-07-01
- Volume
- 74
- Issue
- 7
- Pages
- 863-866
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2167277601
- Cited by
- 290
- References
- 19
- FWCI
- 16.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.